FDA rejects MDMA as psychedelic-based treatment for mental health, PTSD
Federal health officials have declined to approve the psychedelic drug MDMA as a therapy for PTSD.
16 across the spectrum · tap a section to jump
The story so far
2 developments- Aug 9, 2024FDA rejects psychedelic MDMA as treatment for PTSD, calling for additional study
- Aug 10, 2024FDA rejects MDMA as psychedelic-based treatment for mental health, PTSD
Who covered each development
No new developments
Quiet for 780 daysLast development · Aug 10, 2024 — FDA rejects MDMA as psychedelic-based treatment for mental health, PTSD
Left
2 viewpointsFDA declines to approve novel MDMA therapy to treat PTSD, with request for more trial data
FDA rejects MDMA-assisted therapy for PTSD in a setback for psychedelic medicine
Center
11 viewpointsRight
3 viewpointsFDA rejects MDMA as psychedelic-based treatment for mental health, PTSD
FDA won't approve psychedelic MDMA for PTSD, calling for additional study
Veterans advocate for MDMA, also known as ecstasy, to be used in therapy to treat PTSD
Other outlets
International, entertainment and tech outlets, by their rating. Not counted in the bar above. How we count coverage
Left
2 articlesCenter
0 articlesNone
Right
0 articlesNone